Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes
Status:
Terminated
Trial end date:
2005-01-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of arsenic trioxide in treating patients
who have myelodysplastic syndromes.